<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02070744</url>
  </required_header>
  <id_info>
    <org_study_id>VX13-661-103</org_study_id>
    <nct_id>NCT02070744</nct_id>
  </id_info>
  <brief_title>Study to Evaluate Safety and Efficacy of VX-661 in Combination With Ivacaftor in Subjects With Cystic Fibrosis, Homozygous for the F508del-CFTR Mutation With an Open-Label Expansion</brief_title>
  <official_title>A Phase 2, Randomized, Multicenter, Double Blind, Placebo Controlled Study to Evaluate Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of VX-661 in Combination With Ivacaftor for 12 Weeks in Subjects With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation With an Open-Label Extension</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vertex Pharmaceuticals Incorporated</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Vertex Pharmaceuticals Incorporated</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to evaluate the safety and efficacy of VX-661in combination
      with ivacaftor in participants with cystic fibrosis (CF) who are homozygous for F508del
      cystic fibrosis transmembrane conductance regulator (CFTR) mutation
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2014</start_date>
  <completion_date type="Actual">May 27, 2016</completion_date>
  <primary_completion_date type="Actual">May 27, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PC Phase: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)</measure>
    <time_frame>Baseline (PC Phase) up to 112 days</time_frame>
    <description>AE: Any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as Non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, Inpatient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. AEs with start date or increased severity on or after the first dose of study drug through the end of study participation considered treatment-emergent. Baseline was defined as Day 1 of PC Phase.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>OLE Phase: Number of Participants With Treatment-Emergent AEs and SAEs</measure>
    <time_frame>Baseline (OLE Phase) up to 364 days</time_frame>
    <description>AE: Any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as Non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, Inpatient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. AEs with start date or increased severity on or after the first dose of study drug through the end of study participation considered treatment-emergent. Baseline was defined as Day 1 of the OLE Phase.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>PC Phase: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 12</measure>
    <time_frame>Baseline (PC Phase), Through Week 12</time_frame>
    <description>FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Baseline was defined as Day 1 of PC Phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OLE Phase: Absolute Change From Baseline in Percent Predicted FEV1 Through Week 40</measure>
    <time_frame>Baseline (OLE Phase), Through Week 40</time_frame>
    <description>FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Baseline was defined as Day 1 of the OLE Phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PC Phase: Relative Change From Baseline in Percent Predicted FEV1 Through Week 12</measure>
    <time_frame>Baseline (PC Phase), Through Week 12</time_frame>
    <description>FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Baseline was defined as Day 1 of PC Phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OLE Phase: Relative Change From Baseline in Percent Predicted FEV1 Through Week 40</measure>
    <time_frame>Baseline (OLE Phase), Through Week 40</time_frame>
    <description>FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Baseline was defined as Day 1 of the OLE Phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PC Phase: Absolute Change From Baseline in Sweat Chloride Through Week 12</measure>
    <time_frame>Baseline (PC Phase), Through Week 12</time_frame>
    <description>Sweat samples were collected using an approved collection device. Baseline was defined as Day 1 of PC Phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OLE Phase: Absolute Change From Baseline in Sweat Chloride Through Week 40</measure>
    <time_frame>Baseline (OLE Phase), Through Week 40</time_frame>
    <description>Sweat samples were collected using an approved collection device. Baseline was defined as Day 1 of the OLE Phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PC Phase: Absolute Change From Baseline in Body Weight at Week 12</measure>
    <time_frame>Baseline (PC Phase), Week 12</time_frame>
    <description>Baseline was defined as Day 1 of PC Phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OLE Phase: Absolute Change From Baseline in Body Weight at Week 40</measure>
    <time_frame>Baseline (OLE Phase), Week 40</time_frame>
    <description>Baseline was defined as Day 1 of the OLE Phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PC Phase: Absolute Change From Baseline Body Mass Index (BMI) at Week 12</measure>
    <time_frame>Baseline (PC Phase), Week 12</time_frame>
    <description>BMI was calculated using following formula: BMI = Weight in kg/height in square meter (m^2). Baseline was defined as Day 1 of PC Phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OLE Phase: Absolute Change From Baseline BMI at Week 40</measure>
    <time_frame>Baseline (OLE Phase), Week 40</time_frame>
    <description>BMI was calculated using following formula: BMI = Weight in kg/height in m^2. Baseline was defined as Day 1 of the OLE Phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PC Phase: Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through Week 12</measure>
    <time_frame>Baseline (PC Phase), Through Week 12</time_frame>
    <description>The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. Baseline was defined as Day 1 of PC Phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>OLE Phase: Absolute Change From Baseline in CFQ-R Respiratory Domain Score Through Week 40</measure>
    <time_frame>Baseline (OLE Phase), Through Week 40</time_frame>
    <description>The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. Baseline was defined as Day 1 of the OLE Phase.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PC Phase: Maximum Plasma Concentration (Cmax) of VX-661 and IVA</measure>
    <time_frame>Pre-dose, 2, 3, 4, 6, 9 and 12 hours post-dose on Day 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PC Phase: Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours (AUC0-24h) of VX-661</measure>
    <time_frame>Pre-dose, 2, 3, 4, 6, 9 and 12 hours post-dose on Day 85</time_frame>
    <description>Pharmacokinetic (PK) sampling was performed up to 12 hours post-dose on Day 85. For Arm VX-661 50 mg q12h + IVA 150 mg q12h (VX-661 q12h regimen), area under the concentration versus time curve from time 0 to 12 hours (AUC0-12h) was multiplied by 2 to obtain AUC0-24h.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PC Phase: Area Under the Concentration Versus Time Curve From Time 0 to 12 Hours (AUC0-12h) of IVA</measure>
    <time_frame>Pre-dose, 2, 3, 4, 6, 9 and 12 hours post-dose on Day 85</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PC Phase: Time to Reach Cmax (Tmax) of VX-661 and IVA</measure>
    <time_frame>Pre-dose, 2, 3, 4, 6, 9 and 12 hours post-dose on Day 85</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Cystic Fibrosis</condition>
  <arm_group>
    <arm_group_label>PC Phase: VX-661 50 mg q12h + IVA 150 mg q12h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received VX-661 50 milligram (mg) tablet plus Ivacaftor (IVA) 150 mg tablet every 12 hours (q12h) for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PC Phase: VX 661 placebo q12h + IVA placebo q12h</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received placebo matched to VX-661 tablet plus placebo matched to IVA tablet q12h for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PC Phase: VX-661 100 mg qd + IVA 150 mg q12h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received two VX-661 50 mg tablets once daily (qd) plus IVA 150 mg tablet q12h for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PC Phase: VX -661 placebo qd + IVA placebo q12h</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received two placebo matched to VX-661 tablets qd plus placebo matched to IVA tablet q12h for 12 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>OLE Phase: VX-661 100 mg qd + IVA 150 mg q12h</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants who completed 12 week PC phase underwent a washout period of at least 4 weeks before entering the OLE phase and received two VX-661 50 mg tablets qd plus IVA 150 mg tablet q12h for 48 weeks in OLE phase.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>VX-661</intervention_name>
    <description>Tablet, oral use</description>
    <arm_group_label>PC Phase: VX-661 50 mg q12h + IVA 150 mg q12h</arm_group_label>
    <arm_group_label>PC Phase: VX-661 100 mg qd + IVA 150 mg q12h</arm_group_label>
    <arm_group_label>OLE Phase: VX-661 100 mg qd + IVA 150 mg q12h</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ivacaftor</intervention_name>
    <description>Film coated tablet, oral use</description>
    <arm_group_label>PC Phase: VX-661 50 mg q12h + IVA 150 mg q12h</arm_group_label>
    <arm_group_label>PC Phase: VX-661 100 mg qd + IVA 150 mg q12h</arm_group_label>
    <arm_group_label>OLE Phase: VX-661 100 mg qd + IVA 150 mg q12h</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matched to VX-661</intervention_name>
    <description>Tablet, oral use</description>
    <arm_group_label>PC Phase: VX 661 placebo q12h + IVA placebo q12h</arm_group_label>
    <arm_group_label>PC Phase: VX -661 placebo qd + IVA placebo q12h</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo matched to Ivacaftor</intervention_name>
    <description>Film coated tablet, oral use</description>
    <arm_group_label>PC Phase: VX 661 placebo q12h + IVA placebo q12h</arm_group_label>
    <arm_group_label>PC Phase: VX -661 placebo qd + IVA placebo q12h</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Homozygous for the F508del CFTR mutation

          -  FEV1 ≥40% and ≤90% of predicted normal for age, sex, and height

          -  Stable CF disease as judged by the investigator

        Exclusion Criteria:

          -  History of any comorbidity that, in the opinion of the investigator, might confound
             the results of the study or pose an additional risk in administering study drug to the
             participant

          -  Pregnant and nursing females: Females of childbearing potential must have a negative
             pregnancy test at screening and Day 1 of the PC Phase and Day -7 or Day 1 of the OLE
             Phase (whichever was applicable)

          -  Sexually active participants of reproductive potential who are not willing to follow
             the contraception requirements

          -  The participant or a close relative of the participant is the investigator or sub
             investigator, research assistant, pharmacist, study coordinator, or other staff
             directly involved with the conduct of the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Palo Alto</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Stanford</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Altamonte Springs</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Orlando</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boise</city>
        <state>Idaho</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New Brunswick</city>
        <state>New Jersey</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Oklahoma City</city>
        <state>Oklahoma</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Memphis</city>
        <state>Tennessee</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Burlington</city>
        <state>Vermont</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Colchester</city>
        <state>Vermont</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 21, 2014</study_first_submitted>
  <study_first_submitted_qc>February 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 25, 2014</study_first_posted>
  <results_first_submitted>March 14, 2018</results_first_submitted>
  <results_first_submitted_qc>March 14, 2018</results_first_submitted_qc>
  <results_first_posted type="Actual">April 13, 2018</results_first_posted>
  <disposition_first_submitted>June 8, 2017</disposition_first_submitted>
  <disposition_first_submitted_qc>June 8, 2017</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">June 12, 2017</disposition_first_posted>
  <last_update_submitted>March 14, 2018</last_update_submitted>
  <last_update_submitted_qc>March 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 13, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>CF</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrosis</mesh_term>
    <mesh_term>Cystic Fibrosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ivacaftor</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>The study consisted of 2 phases: a randomized, double-blind, placebo-controlled (PC) phase in which participants received either VX-661 in combination with Ivacaftor (IVA), or matched placebo and an open-label extension (OLE) phase in which participants received VX-661 in combination with IVA.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>PC Phase: VX-661 50 mg q12h + IVA 150 mg q12h</title>
          <description>Participants received VX-661 50 milligram (mg) tablet plus IVA 150 mg tablet every 12 hours (q12h) for 12 weeks.</description>
        </group>
        <group group_id="P2">
          <title>PC Phase: VX-661 Placebo q12h + IVA Placebo q12h</title>
          <description>Participants received placebo matched to VX-661 tablet plus placebo matched to IVA tablet q12h for 12 weeks.</description>
        </group>
        <group group_id="P3">
          <title>PC Phase: VX-661 100 mg qd + IVA 150 mg q12h</title>
          <description>Participants received two VX-661 50 mg tablets once daily (qd) plus IVA 150 mg tablet q12h for 12 weeks.</description>
        </group>
        <group group_id="P4">
          <title>PC Phase: VX -661 Placebo qd + IVA Placebo q12h</title>
          <description>Participants received two placebo matched to VX-661 tablets qd plus placebo matched to IVA tablet q12h for 12 weeks.</description>
        </group>
        <group group_id="P5">
          <title>OLE Phase: VX-661 100 mg qd + IVA 150 mg q12h</title>
          <description>Participants who completed 12 week PC phase underwent a washout period of at least 4 weeks before entering the OLE phase and received two VX-661 50 mg tablets qd plus IVA 150 mg tablet q12h for 48 weeks in OLE phase.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>PC Phase (12 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="14"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Treated</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="5"/>
                <participants group_id="P3" count="15"/>
                <participants group_id="P4" count="13"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Randomized, but not treated</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="1"/>
                <participants group_id="P5" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>OLE Phase (48 Weeks)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="27">12 participants completed PC phase, but did not enter OLE phase.</participants>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="24"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Other</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
                <participants group_id="P4" count="0"/>
                <participants group_id="P5" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Full Analysis Set (FAS) was defined as all randomized participants who received at least 1 dose of study drug in PC Phase.</population>
      <group_list>
        <group group_id="B1">
          <title>PC Phase: VX-661 50 mg q12h + IVA 150 mg q12h</title>
          <description>Participants received VX-661 50 mg tablet plus IVA 150 mg tablet q12h for 12 weeks.</description>
        </group>
        <group group_id="B2">
          <title>PC Phase: VX-661 Placebo q12h + IVA Placebo q12h</title>
          <description>Participants received placebo matched to VX-661 tablet plus placebo matched to IVA tablet q12h for 12 weeks.</description>
        </group>
        <group group_id="B3">
          <title>PC Phase: VX-661 100 mg qd + IVA 150 mg q12h</title>
          <description>Participants received two VX-661 50 mg tablets qd plus IVA 150 mg tablet q12h for 12 weeks.</description>
        </group>
        <group group_id="B4">
          <title>PC Phase: VX -661 Placebo qd + IVA Placebo q12h</title>
          <description>Participants received two placebo matched to VX-661 tablets qd plus placebo matched to IVA tablet q12h for 12 weeks.</description>
        </group>
        <group group_id="B5">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
            <count group_id="B2" value="5"/>
            <count group_id="B3" value="15"/>
            <count group_id="B4" value="13"/>
            <count group_id="B5" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33.0" spread="10.6"/>
                    <measurement group_id="B2" value="24.2" spread="2.2"/>
                    <measurement group_id="B3" value="27.3" spread="5.2"/>
                    <measurement group_id="B4" value="30.3" spread="10.8"/>
                    <measurement group_id="B5" value="28.8" spread="8.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="14"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                    <measurement group_id="B4" value="10"/>
                    <measurement group_id="B5" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>PC Phase: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
        <description>AE: Any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as Non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, Inpatient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. AEs with start date or increased severity on or after the first dose of study drug through the end of study participation considered treatment-emergent. Baseline was defined as Day 1 of PC Phase.</description>
        <time_frame>Baseline (PC Phase) up to 112 days</time_frame>
        <population>Safety Set was defined as all participants who received at least 1 dose of study drug in PC Phase.</population>
        <group_list>
          <group group_id="O1">
            <title>PC Phase: VX-661 50 mg q12h + IVA 150 mg q12h</title>
            <description>Participants received VX-661 50 mg tablet plus IVA 150 mg tablet q12h for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PC Phase: VX-661 Placebo q12h + IVA Placebo q12h</title>
            <description>Participants received placebo matched to VX-661 tablet plus placebo matched to IVA tablet q12h for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PC Phase: VX-661 100 mg qd + IVA 150 mg q12h</title>
            <description>Participants received two VX-661 50 mg tablets qd plus IVA 150 mg tablet q12h for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PC Phase: VX -661 Placebo qd + IVA Placebo q12h</title>
            <description>Participants received two placebo matched to VX-661 tablets qd plus placebo matched to IVA tablet q12h for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>PC Phase: Number of Participants With Treatment-Emergent Adverse Events (AEs) and Serious Adverse Events (SAEs)</title>
          <description>AE: Any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as Non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, Inpatient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. AEs with start date or increased severity on or after the first dose of study drug through the end of study participation considered treatment-emergent. Baseline was defined as Day 1 of PC Phase.</description>
          <population>Safety Set was defined as all participants who received at least 1 dose of study drug in PC Phase.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                    <measurement group_id="O2" value="5"/>
                    <measurement group_id="O3" value="15"/>
                    <measurement group_id="O4" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="4"/>
                    <measurement group_id="O4" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>OLE Phase: Number of Participants With Treatment-Emergent AEs and SAEs</title>
        <description>AE: Any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as Non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, Inpatient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. AEs with start date or increased severity on or after the first dose of study drug through the end of study participation considered treatment-emergent. Baseline was defined as Day 1 of the OLE Phase.</description>
        <time_frame>Baseline (OLE Phase) up to 364 days</time_frame>
        <population>Safety Set was defined as all participants who received at least 1 dose of study drug in OLE Phase.</population>
        <group_list>
          <group group_id="O1">
            <title>OLE Phase: VX-661 100 mg qd + IVA 150 mg q12h</title>
            <description>Participants who completed 12 week PC phase underwent a washout period of at least 4 weeks before entering the OLE phase and received two VX-661 50 mg tablets qd plus IVA 150 mg tablet q12h for 48 weeks in OLE phase.</description>
          </group>
        </group_list>
        <measure>
          <title>OLE Phase: Number of Participants With Treatment-Emergent AEs and SAEs</title>
          <description>AE: Any untoward medical occurrence in a participant during the study; the event does not necessarily have a causal relationship with the treatment. This includes any newly occurring event or previous condition that has increased in severity or frequency after the informed consent form is signed. AE includes serious as well as Non-serious AEs. SAE (subset of AE): medical event or condition, which falls into any of the following categories, regardless of its relationship to the study drug: death, life threatening adverse experience, Inpatient hospitalization/prolongation of hospitalization, persistent/significant disability or incapacity, congenital anomaly/birth defect, important medical event. AEs with start date or increased severity on or after the first dose of study drug through the end of study participation considered treatment-emergent. Baseline was defined as Day 1 of the OLE Phase.</description>
          <population>Safety Set was defined as all participants who received at least 1 dose of study drug in OLE Phase.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Participants with AEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Participants with SAEs</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PC Phase: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 12</title>
        <description>FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Baseline was defined as Day 1 of PC Phase.</description>
        <time_frame>Baseline (PC Phase), Through Week 12</time_frame>
        <population>FAS was defined as all randomized participants who received at least 1 dose of study drug in PC Phase.</population>
        <group_list>
          <group group_id="O1">
            <title>PC Phase: VX-661 50 mg q12h + IVA 150 mg q12h</title>
            <description>Participants received VX-661 50 mg tablet plus IVA 150 mg tablet q12h for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PC Phase: VX-661 Placebo q12h + IVA Placebo q12h</title>
            <description>Participants received placebo matched to VX-661 tablet plus placebo matched to IVA tablet q12h for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PC Phase: VX-661 100 mg qd + IVA 150 mg q12h</title>
            <description>Participants received two VX-661 50 mg tablets qd plus IVA 150 mg tablet q12h for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PC Phase: VX -661 Placebo qd + IVA Placebo q12h</title>
            <description>Participants received two placebo matched to VX-661 tablets qd plus placebo matched to IVA tablet q12h for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>PC Phase: Absolute Change From Baseline in Percent Predicted Forced Expiratory Volume in 1 Second (FEV1) Through Week 12</title>
          <description>FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Baseline was defined as Day 1 of PC Phase.</description>
          <population>FAS was defined as all randomized participants who received at least 1 dose of study drug in PC Phase.</population>
          <units>Percent predicted of FEV1</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" lower_limit="-3.1" upper_limit="5.0"/>
                    <measurement group_id="O2" value="-0.1" lower_limit="-4.4" upper_limit="4.3"/>
                    <measurement group_id="O3" value="3.0" lower_limit="0.4" upper_limit="5.5"/>
                    <measurement group_id="O4" value="1.9" lower_limit="-0.9" upper_limit="4.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OLE Phase: Absolute Change From Baseline in Percent Predicted FEV1 Through Week 40</title>
        <description>FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Baseline was defined as Day 1 of the OLE Phase.</description>
        <time_frame>Baseline (OLE Phase), Through Week 40</time_frame>
        <population>Analysis population was defined as all participants who received at least 1 dose of study drug in OLE phase.</population>
        <group_list>
          <group group_id="O1">
            <title>OLE Phase:VX-661 100 mg qd + IVA 150 mg q12h</title>
            <description>Participants who completed 12 week PC phase underwent a washout period of at least 4 weeks before entering the OLE phase and received two VX-661 50 mg tablets qd plus IVA 150 mg tablet q12h for 48 weeks in OLE phase.</description>
          </group>
        </group_list>
        <measure>
          <title>OLE Phase: Absolute Change From Baseline in Percent Predicted FEV1 Through Week 40</title>
          <description>FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Baseline was defined as Day 1 of the OLE Phase.</description>
          <population>Analysis population was defined as all participants who received at least 1 dose of study drug in OLE phase.</population>
          <units>Percent predicted of FEV1</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.7" lower_limit="0.4" upper_limit="4.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PC Phase: Relative Change From Baseline in Percent Predicted FEV1 Through Week 12</title>
        <description>FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Baseline was defined as Day 1 of PC Phase.</description>
        <time_frame>Baseline (PC Phase), Through Week 12</time_frame>
        <population>FAS was defined as all randomized participants who received at least 1 dose of study drug in PC Phase.</population>
        <group_list>
          <group group_id="O1">
            <title>PC Phase: VX-661 50 mg + IVA 150 mg</title>
            <description>Participants received VX-661 50 mg tablet plus IVA 150 mg tablet q12h for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PC Phase: VX-661 Placebo q12h + IVA Placebo q12h</title>
            <description>Participants received placebo matched to VX-661 tablet plus placebo matched to IVA tablet q12h for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PC Phase: VX-661 100 mg qd + IVA 150 mg q12h</title>
            <description>Participants received two VX-661 50 mg tablets qd plus IVA 150 mg tablet q12h for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PC Phase: VX -661 Placebo qd + IVA Placebo q12h</title>
            <description>Participants received two placebo matched to VX-661 tablets qd plus placebo matched to IVA tablet q12h for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>PC Phase: Relative Change From Baseline in Percent Predicted FEV1 Through Week 12</title>
          <description>FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Baseline was defined as Day 1 of PC Phase.</description>
          <population>FAS was defined as all randomized participants who received at least 1 dose of study drug in PC Phase.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" lower_limit="-6.0" upper_limit="11.1"/>
                    <measurement group_id="O2" value="1.0" lower_limit="-8.2" upper_limit="10.3"/>
                    <measurement group_id="O3" value="6.0" lower_limit="0.6" upper_limit="11.3"/>
                    <measurement group_id="O4" value="4.2" lower_limit="-1.5" upper_limit="10.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OLE Phase: Relative Change From Baseline in Percent Predicted FEV1 Through Week 40</title>
        <description>FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Baseline was defined as Day 1 of the OLE Phase.</description>
        <time_frame>Baseline (OLE Phase), Through Week 40</time_frame>
        <population>Analysis population was defined as all participants who received at least 1 dose of study drug in the OLE Phase.</population>
        <group_list>
          <group group_id="O1">
            <title>OLE Phase: VX-661 100 mg qd + IVA 150 mg q12h</title>
            <description>Participants who completed 12 week PC phase underwent a washout period of at least 4 weeks before entering the OLE phase and received two VX-661 50 mg tablets qd plus IVA 150 mg tablet q12h for 48 weeks in OLE phase.</description>
          </group>
        </group_list>
        <measure>
          <title>OLE Phase: Relative Change From Baseline in Percent Predicted FEV1 Through Week 40</title>
          <description>FEV1 is the volume of air that can forcibly be blown out in one second, after full inspiration. Baseline was defined as Day 1 of the OLE Phase.</description>
          <population>Analysis population was defined as all participants who received at least 1 dose of study drug in the OLE Phase.</population>
          <units>Percent change</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.1" lower_limit="1.7" upper_limit="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PC Phase: Absolute Change From Baseline in Sweat Chloride Through Week 12</title>
        <description>Sweat samples were collected using an approved collection device. Baseline was defined as Day 1 of PC Phase.</description>
        <time_frame>Baseline (PC Phase), Through Week 12</time_frame>
        <population>FAS was defined as all randomized participants who received at least 1 dose of study drug in PC Phase. Here, “Number of participants analyzed” signifies those participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>PC Phase: VX-661 50 mg q12h + IVA 150 mg q12h</title>
            <description>Participants received VX-661 50 mg tablet plus IVA 150 mg tablet q12h for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PC Phase: VX-661 Placebo q12h + IVA Placebo q12h</title>
            <description>Participants received placebo matched to VX-661 tablet plus placebo matched to IVA tablet q12h for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PC Phase: VX-661 100 mg qd + IVA 150 mg q12h</title>
            <description>Participants received two VX-661 50 mg tablets qd plus IVA 150 mg tablet q12h for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PC Phase: VX -661 Placebo qd + IVA Placebo q12h</title>
            <description>Participants received two placebo matched to VX-661 tablets qd plus placebo matched to IVA tablet q12h for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>PC Phase: Absolute Change From Baseline in Sweat Chloride Through Week 12</title>
          <description>Sweat samples were collected using an approved collection device. Baseline was defined as Day 1 of PC Phase.</description>
          <population>FAS was defined as all randomized participants who received at least 1 dose of study drug in PC Phase. Here, “Number of participants analyzed” signifies those participants who were evaluable for this outcome measure.</population>
          <units>Millimole per liter (mmol/L)</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="13"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.6" lower_limit="-16.6" upper_limit="-4.6"/>
                    <measurement group_id="O2" value="2.9" lower_limit="-3.0" upper_limit="8.9"/>
                    <measurement group_id="O3" value="-4.7" lower_limit="-8.4" upper_limit="-0.9"/>
                    <measurement group_id="O4" value="0.8" lower_limit="-3.1" upper_limit="4.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OLE Phase: Absolute Change From Baseline in Sweat Chloride Through Week 40</title>
        <description>Sweat samples were collected using an approved collection device. Baseline was defined as Day 1 of the OLE Phase.</description>
        <time_frame>Baseline (OLE Phase), Through Week 40</time_frame>
        <population>Analysis population was defined as all participants who received at least 1 dose of study drug in the OLE Phase. Here, “Number of participants analyzed” signifies those participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>OLE Phase: VX-661 100 mg qd + IVA 150 mg q12h</title>
            <description>Participants who completed 12 week PC phase underwent a washout period of at least 4 weeks before entering the OLE phase and received two VX-661 50 mg tablets qd plus IVA 150 mg tablet q12h for 48 weeks in OLE phase.</description>
          </group>
        </group_list>
        <measure>
          <title>OLE Phase: Absolute Change From Baseline in Sweat Chloride Through Week 40</title>
          <description>Sweat samples were collected using an approved collection device. Baseline was defined as Day 1 of the OLE Phase.</description>
          <population>Analysis population was defined as all participants who received at least 1 dose of study drug in the OLE Phase. Here, “Number of participants analyzed” signifies those participants who were evaluable for this outcome measure.</population>
          <units>mmol/L</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="25"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.6" lower_limit="-9.7" upper_limit="-3.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PC Phase: Absolute Change From Baseline in Body Weight at Week 12</title>
        <description>Baseline was defined as Day 1 of PC Phase.</description>
        <time_frame>Baseline (PC Phase), Week 12</time_frame>
        <population>FAS was defined as all randomized participants who received at least 1 dose of study drug in PC Phase.</population>
        <group_list>
          <group group_id="O1">
            <title>PC Phase: VX-661 50 mg q12h + IVA 150 mg q12h</title>
            <description>Participants received VX-661 50 mg tablet plus IVA 150 mg tablet q12h for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PC Phase: VX-661 Placebo q12h + IVA Placebo q12h</title>
            <description>Participants received placebo matched to VX-661 tablet plus placebo matched to IVA tablet q12h for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PC Phase: VX-661 100 mg qd + IVA 150 mg q12h</title>
            <description>Participants received two VX-661 50 mg tablets qd plus IVA 150 mg tablet q12h for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PC Phase: VX -661 Placebo qd + IVA Placebo q12h</title>
            <description>Participants received two placebo matched to VX-661 tablets qd plus placebo matched to IVA tablet q12h for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>PC Phase: Absolute Change From Baseline in Body Weight at Week 12</title>
          <description>Baseline was defined as Day 1 of PC Phase.</description>
          <population>FAS was defined as all randomized participants who received at least 1 dose of study drug in PC Phase.</population>
          <units>kilogram (kg)</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="-0.4" upper_limit="2.3"/>
                    <measurement group_id="O2" value="1.6" lower_limit="0.1" upper_limit="3.0"/>
                    <measurement group_id="O3" value="0.5" lower_limit="-0.3" upper_limit="1.4"/>
                    <measurement group_id="O4" value="0.3" lower_limit="-0.6" upper_limit="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OLE Phase: Absolute Change From Baseline in Body Weight at Week 40</title>
        <description>Baseline was defined as Day 1 of the OLE Phase.</description>
        <time_frame>Baseline (OLE Phase), Week 40</time_frame>
        <population>Analysis population was defined as all participants who received at least 1 dose of study drug in the OLE Phase.</population>
        <group_list>
          <group group_id="O1">
            <title>OLE Phase: VX-661 100 mg qd + IVA 150 mg q12h</title>
            <description>Participants who completed 12 week PC phase underwent a washout period of at least 4 weeks before entering the OLE phase and received two VX-661 50 mg tablets qd plus IVA 150 mg tablet q12h for 48 weeks in OLE phase.</description>
          </group>
        </group_list>
        <measure>
          <title>OLE Phase: Absolute Change From Baseline in Body Weight at Week 40</title>
          <description>Baseline was defined as Day 1 of the OLE Phase.</description>
          <population>Analysis population was defined as all participants who received at least 1 dose of study drug in the OLE Phase.</population>
          <units>kg</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" lower_limit="-0.2" upper_limit="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PC Phase: Absolute Change From Baseline Body Mass Index (BMI) at Week 12</title>
        <description>BMI was calculated using following formula: BMI = Weight in kg/height in square meter (m^2). Baseline was defined as Day 1 of PC Phase.</description>
        <time_frame>Baseline (PC Phase), Week 12</time_frame>
        <population>FAS was defined as all randomized participants who received at least 1 dose of study drug in PC Phase.</population>
        <group_list>
          <group group_id="O1">
            <title>PC Phase: VX-661 50 mg q12h + IVA 150 mg q12h</title>
            <description>Participants received VX-661 50 mg tablet plus IVA 150 mg tablet q12h for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PC Phase: VX-661 Placebo q12h + IVA Placebo q12h</title>
            <description>Participants received placebo matched to VX-661 tablet plus placebo matched to IVA tablet q12h for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PC Phase: VX-661 100 mg qd + IVA 150 mg q12h</title>
            <description>Participants received two VX-661 50 mg tablets qd plus IVA 150 mg tablet q12h for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PC Phase: VX -661 Placebo qd + IVA Placebo q12h</title>
            <description>Participants received two placebo matched to VX-661 tablets qd plus placebo matched to IVA tablet q12h for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>PC Phase: Absolute Change From Baseline Body Mass Index (BMI) at Week 12</title>
          <description>BMI was calculated using following formula: BMI = Weight in kg/height in square meter (m^2). Baseline was defined as Day 1 of PC Phase.</description>
          <population>FAS was defined as all randomized participants who received at least 1 dose of study drug in PC Phase.</population>
          <units>Kilogram per square meter (kg/m^2)</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.38" lower_limit="-0.08" upper_limit="0.84"/>
                    <measurement group_id="O2" value="0.54" lower_limit="0.03" upper_limit="1.04"/>
                    <measurement group_id="O3" value="0.18" lower_limit="-0.11" upper_limit="0.47"/>
                    <measurement group_id="O4" value="0.11" lower_limit="-0.21" upper_limit="0.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OLE Phase: Absolute Change From Baseline BMI at Week 40</title>
        <description>BMI was calculated using following formula: BMI = Weight in kg/height in m^2. Baseline was defined as Day 1 of the OLE Phase.</description>
        <time_frame>Baseline (OLE Phase), Week 40</time_frame>
        <population>Analysis population was defined as all participants who received at least 1 dose of study drug in the OLE Phase.</population>
        <group_list>
          <group group_id="O1">
            <title>OLE Phase: VX-661 100 mg qd + IVA 150 mg q12h</title>
            <description>Participants who completed 12 week PC phase underwent a washout period of at least 4 weeks before entering the OLE phase and received two VX-661 50 mg tablets qd plus IVA 150 mg tablet q12h for 48 weeks in OLE phase.</description>
          </group>
        </group_list>
        <measure>
          <title>OLE Phase: Absolute Change From Baseline BMI at Week 40</title>
          <description>BMI was calculated using following formula: BMI = Weight in kg/height in m^2. Baseline was defined as Day 1 of the OLE Phase.</description>
          <population>Analysis population was defined as all participants who received at least 1 dose of study drug in the OLE Phase.</population>
          <units>kg/m^2</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" lower_limit="-0.09" upper_limit="0.74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PC Phase: Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through Week 12</title>
        <description>The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. Baseline was defined as Day 1 of PC Phase.</description>
        <time_frame>Baseline (PC Phase), Through Week 12</time_frame>
        <population>FAS was defined as all randomized participants who received at least 1 dose of study drug in PC Phase.</population>
        <group_list>
          <group group_id="O1">
            <title>PC Phase: VX-661 50 mg q12h + IVA 150 mg q12h</title>
            <description>Participants received VX-661 50 mg tablet plus IVA 150 mg tablet q12h for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PC Phase: VX-661 Placebo q12h + IVA Placebo q12h</title>
            <description>Participants received placebo matched to VX-661 tablet plus placebo matched to IVA tablet q12h for 12 weeks.</description>
          </group>
          <group group_id="O3">
            <title>PC Phase: VX-661 100 mg qd + IVA 150 mg q12h</title>
            <description>Participants received two VX-661 50 mg tablets qd plus IVA 150 mg tablet q12h for 12 weeks.</description>
          </group>
          <group group_id="O4">
            <title>PC Phase: VX -661 Placebo qd + IVA Placebo q12h</title>
            <description>Participants received two placebo matched to VX-661 tablets qd plus placebo matched to IVA tablet q12h for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>PC Phase: Absolute Change From Baseline in Cystic Fibrosis Questionnaire-Revised (CFQ-R) Respiratory Domain Score Through Week 12</title>
          <description>The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. Baseline was defined as Day 1 of PC Phase.</description>
          <population>FAS was defined as all randomized participants who received at least 1 dose of study drug in PC Phase.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="15"/>
                <count group_id="O4" value="13"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.6" lower_limit="-3.9" upper_limit="15.1"/>
                    <measurement group_id="O2" value="-4.6" lower_limit="-14.9" upper_limit="5.7"/>
                    <measurement group_id="O3" value="1.0" lower_limit="-5.1" upper_limit="7.0"/>
                    <measurement group_id="O4" value="0.4" lower_limit="-6.2" upper_limit="7.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>OLE Phase: Absolute Change From Baseline in CFQ-R Respiratory Domain Score Through Week 40</title>
        <description>The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. Baseline was defined as Day 1 of the OLE Phase.</description>
        <time_frame>Baseline (OLE Phase), Through Week 40</time_frame>
        <population>Analysis population was defined as all participants who received at least 1 dose of study drug in the OLE Phase.</population>
        <group_list>
          <group group_id="O1">
            <title>OLE Phase: VX-661 100 mg qd + IVA 150 mg q12h</title>
            <description>Participants who completed 12 week PC phase underwent a washout period of at least 4 weeks before entering the OLE phase and received two VX-661 50 mg tablets qd plus IVA 150 mg tablet q12h for 48 weeks in OLE phase.</description>
          </group>
        </group_list>
        <measure>
          <title>OLE Phase: Absolute Change From Baseline in CFQ-R Respiratory Domain Score Through Week 40</title>
          <description>The CFQ-R is a validated participant-reported outcome measuring health-related quality of life for participants with cystic fibrosis. Respiratory domain assessed respiratory symptoms (for example, coughing, congestion, wheezing), score range: 0-100; higher scores indicating fewer symptoms and better health-related quality of life. Baseline was defined as Day 1 of the OLE Phase.</description>
          <population>Analysis population was defined as all participants who received at least 1 dose of study drug in the OLE Phase.</population>
          <units>units on a scale</units>
          <param>Least Squares Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="27"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.6" lower_limit="-5.8" upper_limit="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PC Phase: Maximum Plasma Concentration (Cmax) of VX-661 and IVA</title>
        <time_frame>Pre-dose, 2, 3, 4, 6, 9 and 12 hours post-dose on Day 85</time_frame>
        <population>Analysis population included all participants who received a dose of VX-661 and IVA, whether the participant completed dosing or not and if the dataset(s) supported the noncompartmental analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>PC Phase: VX-661 50 mg q12h + IVA 150 mg q12h</title>
            <description>Participants received VX-661 50 mg tablet plus IVA 150 mg tablet q12h for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PC Phase: VX-661 100 mg qd + IVA 150 mg q12h</title>
            <description>Participants received two VX-661 50 mg tablets qd plus IVA 150 mg tablet q12h for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>PC Phase: Maximum Plasma Concentration (Cmax) of VX-661 and IVA</title>
          <population>Analysis population included all participants who received a dose of VX-661 and IVA, whether the participant completed dosing or not and if the dataset(s) supported the noncompartmental analyses.</population>
          <units>Nanogram per milliliter (ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VX-661</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4890" spread="3150"/>
                    <measurement group_id="O2" value="6460" spread="1240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IVA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1490" spread="1150"/>
                    <measurement group_id="O2" value="1210" spread="585"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PC Phase: Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours (AUC0-24h) of VX-661</title>
        <description>Pharmacokinetic (PK) sampling was performed up to 12 hours post-dose on Day 85. For Arm VX-661 50 mg q12h + IVA 150 mg q12h (VX-661 q12h regimen), area under the concentration versus time curve from time 0 to 12 hours (AUC0-12h) was multiplied by 2 to obtain AUC0-24h.</description>
        <time_frame>Pre-dose, 2, 3, 4, 6, 9 and 12 hours post-dose on Day 85</time_frame>
        <population>Analysis population included all participants who received a dose of VX-661 and IVA, whether the participant completed dosing or not and if the dataset(s) supported the noncompartmental analyses. Here, “Number of participants analyzed” signifies those participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>PC Phase: VX-661 50 mg q12h + IVA 150 mg q12h</title>
            <description>Participants received VX-661 50 mg tablet plus IVA 150 mg tablet q12h for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PC Phase: VX-661 100 mg qd + IVA 150 mg q12h</title>
            <description>Participants received two VX-661 50 mg tablets qd plus IVA 150 mg tablet q12h for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>PC Phase: Area Under the Concentration Versus Time Curve From Time 0 to 24 Hours (AUC0-24h) of VX-661</title>
          <description>Pharmacokinetic (PK) sampling was performed up to 12 hours post-dose on Day 85. For Arm VX-661 50 mg q12h + IVA 150 mg q12h (VX-661 q12h regimen), area under the concentration versus time curve from time 0 to 12 hours (AUC0-12h) was multiplied by 2 to obtain AUC0-24h.</description>
          <population>Analysis population included all participants who received a dose of VX-661 and IVA, whether the participant completed dosing or not and if the dataset(s) supported the noncompartmental analyses. Here, “Number of participants analyzed” signifies those participants who were evaluable for this outcome measure.</population>
          <units>Hour*nanogram per milliliter (hr*ng/mL)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="84900" spread="55900"/>
                    <measurement group_id="O2" value="75500" spread="20300"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PC Phase: Area Under the Concentration Versus Time Curve From Time 0 to 12 Hours (AUC0-12h) of IVA</title>
        <time_frame>Pre-dose, 2, 3, 4, 6, 9 and 12 hours post-dose on Day 85</time_frame>
        <population>Analysis population included all participants who received a dose of VX-661 and IVA, whether the participant completed dosing or not and if the dataset(s) supported the noncompartmental analyses. Here, “Number of participants analyzed” signifies those participants who were evaluable for this outcome measure.</population>
        <group_list>
          <group group_id="O1">
            <title>PC Phase: VX-661 50 mg q12h + IVA 150 mg q12h</title>
            <description>Participants received VX-661 50 mg tablet plus IVA 150 mg tablet q12h for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PC Phase: VX-661 100 mg qd + IVA 150 mg q12h</title>
            <description>Participants received two VX-661 50 mg tablets qd plus IVA 150 mg tablet q12h for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>PC Phase: Area Under the Concentration Versus Time Curve From Time 0 to 12 Hours (AUC0-12h) of IVA</title>
          <population>Analysis population included all participants who received a dose of VX-661 and IVA, whether the participant completed dosing or not and if the dataset(s) supported the noncompartmental analyses. Here, “Number of participants analyzed” signifies those participants who were evaluable for this outcome measure.</population>
          <units>hr*ng/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14700" spread="11600"/>
                    <measurement group_id="O2" value="10100" spread="4890"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>PC Phase: Time to Reach Cmax (Tmax) of VX-661 and IVA</title>
        <time_frame>Pre-dose, 2, 3, 4, 6, 9 and 12 hours post-dose on Day 85</time_frame>
        <population>Analysis population included all participants who received a dose of VX-661 and IVA, whether the participant completed dosing or not and if the dataset(s) supported the noncompartmental analyses.</population>
        <group_list>
          <group group_id="O1">
            <title>PC Phase: VX-661 50 mg q12h + IVA 150 mg q12h</title>
            <description>Participants received VX-661 50 mg tablet plus IVA 150 mg tablet q12h for 12 weeks.</description>
          </group>
          <group group_id="O2">
            <title>PC Phase: VX-661 100 mg qd + IVA 150 mg q12h</title>
            <description>Participants received two VX-661 50 mg tablets qd plus IVA 150 mg tablet q12h for 12 weeks.</description>
          </group>
        </group_list>
        <measure>
          <title>PC Phase: Time to Reach Cmax (Tmax) of VX-661 and IVA</title>
          <population>Analysis population included all participants who received a dose of VX-661 and IVA, whether the participant completed dosing or not and if the dataset(s) supported the noncompartmental analyses.</population>
          <units>hour</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="15"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>VX-661</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.48" lower_limit="1.75" upper_limit="4.08"/>
                    <measurement group_id="O2" value="3.23" lower_limit="1.92" upper_limit="6.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>IVA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.59" lower_limit="1.98" upper_limit="6.00"/>
                    <measurement group_id="O2" value="4.00" lower_limit="2.98" upper_limit="6.03"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline (Day 1 of PC Phase) up to 112 days (Placebo control phase); Baseline (Day 1 of OLE Phase) up to 364 days (OLE phase)</time_frame>
      <desc>Safety Set was defined as all participants who received at least 1 dose of study drug in PC Phase and OLE Phase.</desc>
      <group_list>
        <group group_id="E1">
          <title>PC Phase: VX-661 50 mg q12h + IVA 150 mg q12h</title>
          <description>Participants received VX-661 50 mg tablet plus IVA 150 mg tablet q12h for 12 weeks.</description>
        </group>
        <group group_id="E2">
          <title>PC Phase: VX 661 Placebo q12h + IVA Placebo q12h</title>
          <description>Participants received placebo matched to VX-661 tablet plus placebo matched to IVA tablet q12h for 12 weeks.</description>
        </group>
        <group group_id="E3">
          <title>PC Phase: VX-661 100 mg qd + IVA 150 mg q12h</title>
          <description>Participants received two VX-661 50 mg tablets qd plus IVA 150 mg tablet q12h for 12 weeks.</description>
        </group>
        <group group_id="E4">
          <title>PC Phase: VX -661 Placebo qd + IVA Placebo q12h</title>
          <description>Participants received two placebo matched to VX-661 tablets qd plus placebo matched to IVA tablet q12h for 12 weeks.</description>
        </group>
        <group group_id="E5">
          <title>OLE Phase: VX-661 100 mg qd + IVA 150 mg q12h</title>
          <description>Participants who completed 12 week PC phase underwent a washout period of at least 4 weeks before entering the OLE phase and received two VX-661 50 mg tablets qd plus IVA 150 mg tablet q12h for 48 weeks in OLE phase.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="6" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Congenital, familial and genetic disorders</title>
            <event_list>
              <event>
                <sub_title>Cystic fibrosis related diabetes</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Intestinal obstruction</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infective pulmonary exacerbation of cystic fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Dehydration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Nephrolithiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="1" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="15" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="13" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="25" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Ear and labyrinth disorders</title>
            <event_list>
              <event>
                <sub_title>Tinnitus</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dyspepsia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Abdominal distension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Abdominal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Abdominal pain upper</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Haemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Peptic ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal reflux disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Peripheral swelling</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Non-cardiac chest pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Vaccination site discomfort</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Infective pulmonary exacerbation of cystic fibrosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="5" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="4" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="13" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Bacterial vaginosis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Chronic sinusitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Oral candidiasis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Viral upper respiratory tract infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Vulvovaginal mycotic infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Tooth infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Arthropod bite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Muscle strain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Pulmonary function test decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Weight decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Alanine aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Aspartate aminotransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>C-reactive protein increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Heart rate increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Blood bilirubin unconjugated increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Blood triglycerides increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Breath sounds abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Gamma-glutamyltransferase increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Urine output decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Forced expiratory volume decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Vitamin D decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Activated partial thromboplastin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Oxygen saturation decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Prothrombin time prolonged</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Vitamin A decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Vitamin K decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>White blood cells urine positive</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Gout</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Iron deficiency</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Vitamin E deficiency</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Arthritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Muscle spasms</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Musculoskeletal pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pain in extremity</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Lipoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Hyposmia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Lethargy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Sinus headache</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Somnolence</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Disorientation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Menorrhagia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Testicular pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Amenorrhoea</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Breast tenderness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="5" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="10" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Haemoptysis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="3" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Respiration abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Nasal congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="3" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Lower respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Sputum increased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="2" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="4" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Sputum discoloured</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Epistaxis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Nasal oedema</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Painful respiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Paranasal sinus hypersecretion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Productive cough</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Sinus congestion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="5" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Wheezing</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="2" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Rales</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pleurisy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pleuritic pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Pneumothorax</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="3" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract congestion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Acne</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Dermatitis allergic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="1" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
              <event>
                <sub_title>Rash</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="6"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="5"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="13"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="27"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>PI is free to publish results of the study after (1) the first multi-center publication, (2) if the sponsor elects not to publish the results, or (3) 18 months after close of the study, whichever occurs first. Proposed publications are to be submitted to the sponsor for review and comment for a period of at least 45 days (which may be extended under certain circumstances related to protection of intellectual property); the sponsor cannot require changes to the proposed publications.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Medical Monitor</name_or_title>
      <organization>Vertex Pharmaceuticals Incorporated</organization>
      <phone>617-341-6777</phone>
      <email>medicalinfo@vrtx.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

